Second cranio-facial malignancies in hereditary retinoblastoma survivors previously treated with radiation therapy: Clinic and radiologic characteristics and survival outcomes  by Rodjan, Firazia et al.
European Journal of Cancer (2013) 49, 1939 –1947A v a i l a b l e a t w w w . s c i e n c e d i r e c t . c o m
jour na l homepage : www.e jcancer . in foSecond cranio-facial malignancies in hereditary 
retinoblastoma survivors previously treated with radiation therapy:
Clinic and radiologic characteristics and survival outcomes Firazia Rodjan a,⇑, Pim de Graaf a, Herve ´ J. Brisse b, Jonathan I.L.M. Verbeke a,
Esther Sanchez a, Paolo Galluzzi c, Sophia Go¨ricke d, Philippe Maeder e, Isabelle Aerts f,
Remi Dendale g, Laurence Desjardins h, Sonia de Franscesco i, Norbert Bornfeld j,
Wolfgang Sauerwein k, Maja Beck Popovic l, Dirk L. Knol m, Annette C. Moll n,
Jonas A. Castelijns aa Department of Radiology, VU Universit y Medical Center, Amsterdam , The Netherlands 
b Departme nt of Radiology, Institut Curie, Paris, France 
c Department of Neuroim aging and Neurointerventio nal (NINT), Azienda Ospedal iera e Universit aria Santa Maria alle Scotte Siena, Italy 
d Departme nt of Diagnostic and Interventiona l Radiology and Neuroradiolo gy, Universit y Hospital Essen, Germany 
e Department of Radiol ogy, Univers ity Hospital, Lausanne, Switzerland 
f Departme nt of Pediatri c Oncology, Institut Curie, Paris, France 
g Department of Radiothera py, Institut Curie, Paris, France 
h Departme nt of Ophtalmolo gy Surgery, Institut Curie, Paris, France 
i Department of Ophtalmolo gy, Azienda Ospedal iera e Universit aria Santa Maria alle Scotte Siena, Italy 
j Department of Ophtalmolo gy, University Hospital Essen, Germany 
k Departme nt of Radiatio n Oncology, Universit y Hospital Essen, Germany 
l Department of Pediatric Hemato logy–Oncology Unit, University Hospital, Lausanne, Switzerla nd
m Department of Epidemiolog y and Biostatistics [5], VU University Medical Center, Amsterdam , The Netherla nds 
n Departme nt of Ophtalmolo gy, VU University Medical Center, Amsterdam, The Netherlands 
Received 19 July 2012; received in revised form 8 January 2013; accepted 15 January 2013 
Available online 14 February 2013 09
ht
⇑
NKEYWORDS
Paediatric oncology 
Radiation therapy 
MR imaging 
CT-scan
Retinoblastoma
Radiology59-8049  2013 Elsevier Ltd
tp://dx.doi.org/10.10 16/j.ejca.
Correspon ding author: Add
etherlands . Tel.: +31 (0)20 4
E-mail address: f.rodjan@v.
2013.0 1.0
ress: VU
443047; f
umc.nl (F
Open accAbstract Introduction: Hereditary retinoblastoma survivors have an increased risk for cra- 
nio-facial second primary tumours (SPT), especially after treatment with external beam radio- 
therapy (EBRT). This multicentre study evaluates the clinical and imaging characteristics and 
outcomes of cranio-facial SPTs in irradiated retinoblastoma survivors.
Patients and Methods: Clinical and radiological data of 42 hereditary retinoblastoma patients 
with 44 second and third malignancies were reviewed. Radiological data included anatomic 
location and computed tomography (CT) and magnetic resonance (MR) characteristics.10 
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tumoursCox regression and likelihood ratio chi-square test were used to evaluate differences in
patients’ survival rates.
Results: Cranio-facial SPTs were diagnosed at a median age of 13 years. Histological types 
included osteosarcomas (43%), rhabdomyosarcomas (20%) (57% embryonal, 43% alveolar)
and a variety of other types of SPT (37%). Predilection sites were: temporal fossa (39%), eth- 
moid sinus (23%), orbit (18%), maxillary sinus (16%) and intracranial dura mater (4%). Most 
of the osteosarcomas (78%) and rhabdomyosarcomas (80%) occurred in patients treated with 
EBRT in the ﬁrst year-of-life. Treatment of SPTs with a microscopically complete surgical 
resection led to a signiﬁcantly better 5-year overall survival (OS) (P = 0.017) and event-free 
survival (EFS) (P = 0.012) compared to patients treated without surgery or incomplete resec- 
tion (OS: 83% versus 52%; EFS: 80% versus 47%).
Conclusions: Osteosarcomas and rhabdomyosarcomas are the most common cranio-facial 
SPTs in irradiated hereditary retinoblastoma survivors, which develop in speciﬁc locations 
and occur predominantly in patients irradiated in their ﬁrst year-of-life. Microscopically com- 
plete surgical resection of SPTs is a major prognostic factor, suggesting the potential beneﬁt of
early detection by imaging.
 2013 Elsevier Ltd. All rights reserved.1. Intro duction 
Hereditar y Rb survivo rs are at great er risk of devel- 
oping second primary tumou rs (SPTs)1 because of
RB1-gene germl ine mutation. In developed countri es,
SPTs are the leadi ng cause of death in patie nts with 
hereditary Rb.2–6
The incide nce of SPTs in hereditary Rb is 8.4% at
18-yea rs and 36% at 50-yea rs after diagn osis.3,4,6–9
External beam radiotherap y (EBRT) increa ses the risk 
for subsequen t malignant neo plasms, as up to 70% of
SPTs in Rb patients develop insi de or at bounda ries 
of the irradiat ion ﬁeld.3,4,6,10–14 The age of Rb-diagno -
sis and subsequent ly age of irra diation is an addition al
risk facto r: patien ts irradiat ed during the ﬁrst year of- 
their-l ife develop two to eight times more SPTs than 
patien ts irradiat ed after one year.15–17 The combina- 
tion of EBRT and chemot herapy in hereditary Rb
patien ts also sli ghtly increases the risk for SPT devel- 
opment compared to EBR T alone.4 Most common 
histologic al types of SPT in irradiat ion ﬁelds are oste- 
osarcom a, rhab domyosar coma, leiom yosarcom a, other 
soft tissue sarcom as, mening ioma 12,13,18,19 and rarely 
carcin omas.8,9
Progno sis of cran io-facia l SPTs in Rb survi vors is
poor despit e agg ressive treatment . One major pro gnostic 
factor of these tumour s is the feasibil ity of complete 
resection of the SPT 20 and theref ore early diagn osis is
crucia l.
Compu ted tomogr aphy (CT)- and magnetic reso- 
nance (MR) imaging features of Rb are wel l docu -
mente d. To our knowl edge howeve r, except for case 
report s,18,19 there is only one study 16 descri bing the 
spectru m of imag ing charact eristic s of cranio- facial 
SPTs in Rb survi vors.
This mult icentre study evaluates the clinical and 
imaging charact eristic s and outcomes of cranio- facial 
SPTs in irradiat ed hereditary Rb survi vors.2. Patien ts and methods 
2.1. Study popula tion 
Thi s retr ospecti ve study origi nated from an interna- 
tional partner ship of ﬁve Rb-r eferen ce centres Euro pean 
Retinoblas toma Imagin g Collaborat ion (ERIC) from 
Paris, Essen, Lausann e, Siena and Amster dam in agree- 
ment with the recomm endati ons of each local ethic s
committ ee or inst itutional review board. Patient records 
from 1989 and 2010 were revie wed and SPTs wer e
included by both ophthalm ologists and onc ologists from 
the Rb-r eferen ce cen tres. The followi ng inclusion crite- 
ria wer e set: (1) a cranio-faci al second or thir d malig- 
nancy in a hereditary retin oblastoma patient 
(conﬁrmed by ocu lar funduscop y, imaging or hist opa- 
thology ), (2) EBRT for retinob lastoma, (3) availabil ity 
of adequate CT or MRI of the SPT. Patient s with either 
metastat ic tumour , retinob lastoma recurr ence or trilat- 
eral retinob lastoma were not included in the present 
study. For ty-four secon d and third mali gnancies in 42
patients were included in this retro spective study. In
the majorit y of patients the EBRT planning designs 
could not be retrieved from the medic al records and
were not digitally avail able, theref ore a clear deﬁnition 
of the radiation ﬁelds and bounda ries is lacki ng.
2.2. Clinical data and primary reti noblastom a treat ment 
Clinical record s were evaluated for patien ts’ age (at
time of Rb-diagno sis, EBRT treat ment and SPT-d iag- 
nosis), presence of RB1-mut ation, treatmen t of Rb and 
radiation dose. Patient s with bilateral Rb, a positive 
family history of Rb or a RB1-gene mutation wer e clas- 
siﬁed as “heredit ary ”. Symptom s associ ated with SPT at
ﬁrst presentati on, hist opatholog ical type of SPT and 
treatment for SPT wer e also recorded. Delay of SPT- 
diagnosis was calcul ated as the tim e elapse d from onset 
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or biopsy). Surgica l treatmen t was categor ised as com- 
plete or incompl ete microscop ic resect ion. The deﬁnition
of micr oscopic complete resect ion was based on both 
patholog ical and surgi cal infor mation . Microscop ic
complet e resect ion was deﬁned as if (macroscopi call y)
the whol e tumour was resect ed, with free resect ion mar- 
gins at hist opatholog y without macros copic residu al
tumour on follo w-up imag ing. Time- intervals were cal- 
culat ed from EBRT to SPT- diagnosi s, and SPT-d iagno- 
sis to death or last follo w-up date. Clinical data of part 
of this patient-cohor t wer e previous ly report ed.4,62.3. Imag ing data and analys is
Only pre-treat ment imag es of SPTs were assessed to
avoid treatment eﬀects. Thi rty-thre e MR scans were 
availa ble for revie w includin g unen hanced T1-we ighted 
imag es in all patients and post- contrast T1-w eighted 
imag es and T2-weight ed imag es. In addition, 22 CT- 
scans wer e ava ilable for review includi ng 18 con trast- 
enhan ced CT-e xamin ations. In 11 out of 44 tumou rs
both MR and CT were availab le.
Image s wer e scored for locat ion of SPT and involv e-
ment of bone s and muscles in the cranio-faci al area.
Tumo ur location was afte rwards categor ised in predil ec- 
tion sites based on the presum ed origi n of the SPTs; an
anatom ical compart ment or struc ture which contai ned 
the majorit y of the tumour mass. Addition al parame ters 
included regarding tumour spread into neighbou ring 
anatom ical compart ments and struc tures (e.g. spread 
into the paranasa l sinuse s, orbit, intr acrani al, cavernou s
sinus and pteryg opa latine fossa), perineur al spread,
invasi on through the skullbase and vessel encasemen t
or invasion .
MRI and CT charact eristic s for SPTs included 
tumour border (ill- or well- deﬁned), enhanc ement 
(homo- or heterog eneo us) and necrosi s (yes/no). SPTs 
on MRI were also evaluated for signal intens ity (SI) as
compared to nor mal muscl es on T1- and T2-weight ed
imag es (hypo-, iso- and hyperinte nse) and on CT
(hypo-, iso- and hyperd ense) for calciﬁcations and den -
sity of the tumour .2.4. Statisti cs
All data were statistica lly analys ed using SPSS, ver- 
sion 15.0 (SPSS, Chi cago III). Men ingiomas were 
excluded from the survi val analys is. For eve nt-free sur- 
vival analys is (EFS), an event was consider ed as if a
relaps e of the SPT (local recurr ence or meta stas es) or
cranio- facial third primary tumour occurred. Cox 
regres sion was used to evaluat e diﬀerences in EFS and 
overal l survi val (OS) in patien ts treated with or without 
complet e microscop ic tumour resect ion by the likeli- 
hood ratio chi-square test . The 95% con ﬁdence inter vals (CIs) at 5-year survi val were calcul ated for the EFS and 
OS. The associ ation betw een complet e micr oscopic 
tumour resect ion and complete disease remissi on was 
analys ed by the likel ihood rati o chi-squ are test. Diﬀer-
ences betw een histo patholog ical sub types and age at
SPT-d iagnosis were analyse d using analysis of varian ce.3. Res ults 
3.1. Clinic al charact eristics 
Patient and treatmen t characteris tics are descri bed in
Table 1. All patients had heredit ary retin oblasto ma.
EBRT was performed at a mean age of 11 months ,
and before 1-year of age in 69% of patie nts. Data 
regardi ng EBR T dose were avail able in all but two 
patien ts. A mean dose of 45 Gy (range 40–50 Gy) was 
delive red in 15–25 fractions of 2 or 3 Gy. Fourteen 
patien ts (33%) also recei ved chemot herapy. Chem other- 
apy regim en included cyclopho sphamid e in 10, vincri s-
tine in 11, acti nomyci n in four, carbopla tin in two,
etoposi de in two and cisplati n in two patients. In one 
patien t chemot herapy data could not be retrieved.
SPTs were diagnose d at a media n age of 13 years 
(range, 3–38 years). TPT (two patients) occurred at a
media n age of 15 years. Mean tim e-interva l from EBRT 
to developm ent of SPT was 15 years with a range of 3–
37 years. In our study popul ation, EBRT perfor med 
within the ﬁrst year-of-lif e led to SPTs afte r a mean 
interval of 14 years compared to 17 years when per-
forme d afte r the ﬁrst year-o f-life.
Delay of diagno sis between onset of sympt oms to
conﬁrmation of SPT was 56 days (mean 256 days, range 
6–707 days). The most frequent present ing symptom 
was local swelling (60%). Othe r sympt oms included :
local pain (14%), headache (19%), sinus sympt oms (epi-
staxis [7%] and persisting rhinorr hoea [5%]), not-ﬁtting 
eye-pr othesis (10%), sympt oms of intracrani al hyperten- 
sion (5%) and ptosi s (5%).3.2. Treatm ent of SPTs 
Forty patients unde rwent treatment for SPT which 
included chemo therapy in 35 patien ts (88%), surger y in
25 patien ts (64%) (out of whic h only seven patien ts
showe d a micr oscopic complet e tumou r resect ion),
EBRT in four patients (10%) and brachyt herapy in three 
patien ts (8%). Two patients received only palliative care 
because of extens ive tumou r spread.3.3. Clini cal and radio logical charact eristics accordi ng to
histopat hological subtypes 
The 44 cran io-facia l SPTs and TPTs were categor ised 
in the follo wing ﬁve groups: osteosarcomas (17 SPTs 
and two TPTs), rha bdomyosar comas (nine SPTs), othe r
Table 1
Patient characteri stics of retinoblas toma patients with SPT.
Characte ristic No. patients (n = 42)
Hereditary retinoblas toma 42
Median age Rb-diagno sis in M (mean, range) 8 (10, 0–36)
Median age EBRT in M (mean, range) 10 (11, 1–37)
Median age SPT in Y (mean, range) 13 (15, 3–38)
Sex 
Male 19
Female 23
Positive RB1-gene mutatio n 35
Treatmen t Rb
Enucleation eye 28
EBRT 42
Unilateral 28
Bilateral 14
Chemotherapy 14
EBRT in ﬁrst year-of-life 29
Rb = retinoblas toma, M = months, Y = years.
Table 3
Computed tomograp hy (CT) and magnetic resonan ce (MR) imaging 
characteri stics of osteosarcom a and rhabdomyo sarcoma in %.
Osteosa rcoma Rhabdomy osarcoma 
Mean TV in cm3(range) 107 (0.4–411) 91 (12–330)
Border 
Well-deﬁned 88 (23) 100 (10)
Ill-deﬁned 12 (3) 0
Necrosis 
Yes 65 (17) 50 (5)
No 27 (7) 50 (5)
NA 8 (2) 0
EP
Homogen eous 4 (1) 15 (2)
Heterogene ous 86 (22) 75 (7)
NA 12 (3) 10 (1)
SI T1-W (MR)
Hypointens e 21 (3) 0
Isointense 71 (10) 100 (8)
Hyperintens e 7 (1) 0
SI T2-W (MR)
Hypointens e 21 (3) 0
Isointense 7 (1) 25 (2)
Hyperintens e 64 (9) 75 (6)
NA 7 (1) 0
Density (CT)
Hypodense 17 (2) 50 (1)
Isodense 17 (2) 50 (1)
Hyperden se 25 (3) 0
NA 42 (5) 0
Calciﬁcations (CT)
Yes 50 (6) 50 (1)
No 33 (4) 50 (1)
NA 17 (2) 0
TV = tumorvolum e, EP = enhancem ent pattern, SI T1-W = signal 
intensity on T1-weighted images SI T2-W = signal intensity on T2- 
weighted images, (absolute values in brackets), NA = not available.
1942 F. Rodjan et al. / European Journal of Cancer 49 (2013) 1939–1947sarcom as, carci nomas and miscell aneous tumou rs (16
SPTs) (Table 2). Imaging characteris tics for osteosarco -
mas and rhabdo myosarco mas are summ aris ed in
Table 3.
More osteos arcoma s and rhabdo myosarco mas were 
found in Rb survivors treated with EBR T within the 
ﬁrst year-o f-life compared to EBR T after the ﬁrst
year-o f-life althoug h this diﬀerence was not signi ﬁcant
(P = 0.07). The media n age of occurrence of SPT was 
signiﬁcantly younger for the two major hist ological 
types (P = 0.008 for osteos arcoma s and P = 0.003 for 
rhabomyos arcoma s) than for the others . In the sub -
group of 14 patie nts treated with a combinat ion of
EBRT and chemot herapy, no signi ﬁcant correlati ons 
were found regarding hist opatholog y, age at presenta -
tion or predilection sites of SPTs compared to patien ts
treated for Rb with EBR T alone.Table 2
Histopat hology and age at diagnosis of 44 second and third primary 
tumours.
Histopat hological subgroups Number Median age 
in years 
(mean, range)
Osteosa rcoma 19 13 (14, 5–20)
Rhabdo myosarcoma 9 11 (11, 5–22)
Other sarcomas 8 22 (23, 15–36)
Leiomyosar coma 2
Undiﬀerentiated sarcoma 5
Liposarcoma 1
Carcinom as 5 16 (19, 7–38)
Sebaceous gland carcinoma 1
Undiﬀerentiated spindle cell carcinoma 3
Sinonasal neuroendoc rine carcinoma 1
Miscellaneo us 3 11 (14, 3–28)
Meningeom a 2
Esthesioneuro blastoma 1Tum our origi n was sub divided into ﬁve predilecti on
sites; tempor al fossa (39%), ethmoi d sinus (23%), orb it
(18%), superi or maxilla ry (16%) and intrac ranial dura 
mater (4%).3.4. Osteosar coma 
Ost eosarcom a was the most frequent histo logical 
subtype (43%, 19/ 44), includi ng two TPTs. Four teen 
osteosarco mas (78%) developed in patients treated with 
EBRT within the ﬁrst year-o f-life. Median age for oste- 
osarcom a diagn osis was 13 years (range, 5–20 years).
The orbit (36%) (Fig. 2) and tempor al fossa (36%) were 
the predil ection sites in this group, Fig. 1. In patients 
with osteosarco mas with EBR T afte r the ﬁrst year-of- 
life, the tempor al fossa (50%) was mostly aﬀected. All 
osteosarco mas in the maxilla ry sinus and 83% in the 
orbit were also pre sent in this group. Nine out of 18
patients (50%) with osteos arcoma died (mean interva l,
Fig. 1. Typical location of osteosarcom a originating from the lateral 
orbital wall (greater wing of the sphenoid) and temporal bone with 
extension into the temporal fossa in a 12 years-old girl with bilateral 
retinoblas toma. The tumour was treated with chemotherap y only after 
parental refusal for surgery. This girl died 3 years after diagnosis due 
to local disease progressio n.
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remissi on (mean foll ow-up of 87 months).3.5. Rhab domyo sarcoma 
Rhabdomy osarco ma was the second most common 
SPT (20%, 9/44) includi ng fou r embryonal and three 
alveol ar sub types (data not available for two patients).
Median age of rhabdo myosar coma was 11 years (range
5–22 years). Eight out of nine rhabdo myosar comas wer e
detect ed in patien ts irrad iated in the ﬁrst yea r-of-life,
with the ethmoi d (50%) (Fig. 2a and b) and tempor al
fossa (38%) as predo minantly aﬀected sites. Only one 
tumour develop ed in a patie nt irradiat ed afte r the ﬁrst
year; tumour occurred in the tempor al fossa. In total ,
four out of nine rhabd omyosar coma patie nts died afte r
a mean foll ow-up of 77 mon ths (range 5–154). Three 
patie nts died due to diseas e pro gression and one patie nt
died 154 months after SPT-diagno sis from a TPT (oste-
osarcom a) occu rring 6 years afte r rhabdo myosar coma.
Five patie nts are still in complete remi ssion (mean fol- 
low-up , 68 months ).3.6. Other second primary tum ours 
A variety of other types of SPTs after irra diation 
were divide d into; oth er sarcom as, carcinomas and mis -
cellan eous tumour s (Table 2). In eight patients with
EBRT in the ﬁrst year-o f-life, ﬁve (63%) were other sar- comas, two (25%) carcin omas and one (12%) miscella -
neous tumour s. The tempor al fossa (40%) and ethmoi d
sinus (40%) wer e the predil ection sites for patien ts irra -
diated within their ﬁrst year- of-life.3.7. Surviva l
At the study tim e poin t, 20 patie nts were still alive 
(mean interval, 82 months; media n, 73 months ; range ,
17–168 months ) since SPT- diagnosi s. Among these 20
patien ts, 19 wer e in complet e remi ssion (including three 
patien ts in second comp lete remi ssion). One patie nt was 
diseas e free and lost to follow- up 1 month afte r com-
plete microscop ic tumour resection. Twent y-two 
patien ts died from diseas e progres sion (mean inter val,
51 months; median, 32 months; range, 6 days–244 months)
from diagnosi s.
A signiﬁcantly bette r 5-year OS (P = 0.017) (Fig. 3a)
and EFS (P = 0.012) (Fig. 3b) wer e observed in patie nts 
with complet e micr oscopic tumour resect ion and 5-year 
OS and EFS wer e respect ivel y 83% (95% CI 54–100%)
and 80% (95% CI 45–100%). Com plete microscop ic
tumour resection also showed a statist ically signiﬁcant
correl ation with complet e disease remi ssion (P = 0.036)
(Fig. 4). In patien ts with incompl ete resection, the 5-year 
OS and EFS wer e 52% (95% CI 34–70%) and 47% (95%
CI 29–64%) respect ively. Tumo ur location (P = 0.38),
histop atholog ical sub type (P = 0.33) and age of EBR T
(<1 year; >1 year) (P = 0.53) wer e not associated with 
a signi ﬁcant diﬀerence in survi val.4. Discuss ion 
Osteosar coma and rhabd omyosar coma are the most 
common histo patholog ical subtypes of cran io-facia l
SPTs in irra diated hereditary retino blastoma patie nts,
accoun ting for 64% of all SPTs in our study. Most oste- 
osarcom as are prim arily locat ed in the orb it or tempor al
fossa and rhabdo myosar comas in the ethmoi d sinus or
tempor al fossa. Heredi tary Rb-pa tients irrad iated in
their ﬁrst year-of-lif e have a higher risk of SPTs since 
79% of osteos arcoma s, 89% of rhabdomyos arcoma s
and 63% of the other sarcomas deve lop in this group 
of children.21
In our study, the major ity of the patie nts compla ined 
about a local swe lling, somet imes combined with local 
pain as previous ly descri bed.20 The lymph nodes in the 
neck are usuall y not involv ed. Physici ans should realise 
that otherw ise innocen t sympt oms, such as a combination 
of chronic headache and sinus sympt oms, may be poten -
tially indica tive for cranio- facial SPTs.8 These (chronic)
sympt oms in irradiat ed hereditary Rb-pa tients should 
alert physici ans to perform imag ing without delay in
order to detect SPTs at a potentiall y curative stage .
Radio logists sho uld realise that cranio- facial SPTs in
these patien ts occu r in speciﬁc predilecti on sit es. Most
Fig. 2. A 13-year-o ld girl presenting with a second and third primary tumour after bilateral EBRT at 2 months of age. An embryonal 
rhabdomyosa rcoma of the right ethmoid sinus (a and b) occurred at 13 years of age, which was treated with chemotherap y, surgery and 
brachytherap y. During follow-up for this second primar y tumour, the patient complained about a painful swelling under the left eye and magnetic 
resonance imagin g (MRI) demonstrated an osteosarcoma originati ng from the orbital ﬂoor with soft-tissue invasion (small arrow) (e).
Retrospect ively, this tumour could be observed 6 months and 2 months earlier without soft-tissue invasio n (c and d). This third primary tumour 
was treated with chemother apy, extensive surgery and brachytherapy. Both tumours were completely resected and this girl is still in second 
complete remission .
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Fig. 3. Overall survival curve (P = 0.017) (a) and event-free survival 
curve (P = 0.012) (b) showin g the eﬀects of comple te (n = 7, dotted 
line) and incompl ete (n = 33, solid line) microscopic tumour resection 
in 40 retinoblas toma patients with second primary cranio-facia l
tumours.
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patie nts treated with EBR T before 1 year- of-ag e. In the 
subgrou p of 14 patie nts treat ed with a combinat ion of
EBRT and che motherap y, no signiﬁcant correla tion 
was obs erved regardin g histopa thology , age at present a-
tion or predilecti on sites of SPTs compared to patie nts 
treated for Rb with EBRT alone . Osteo sarcomas fre- 
quen tly originated from the orbit and rhabd omyosar co- 
mas from the ethmoi d. Signal intens ity or den sity is
nonsp eciﬁc for a speciﬁc hist ologic al type, althoug h cal- 
ciﬁcations are present in at least 50% of osteos arcoma s.
Tateis hi et al.16 report ed imag ing charact eris tics (MRI
or CT) of SPTs in the irra diated ﬁeld in 15 patients,
and onl y for osteos arcoma s centra l calciﬁcation was 
found as impor tant ﬁnding on CT. Ther efore, any solid 
tissue mass should prompt to perfor m a biopsy for 
tumour identiﬁcation without delay.
Progn osis of Rb patie nts with SPTs depend s on pos- 
sible treatment strategi es. SPTs in the irra diated area,
treated by a radica l surgical app roach in combination 
with chemot herapy and/or re-i rradiati on, sho w a bette r
survi val comp ared to cases without combined aggres sive 
treatment .22 Re-irrad iation howeve r, has an increa sed 
risk of compli cations due to post-radia tion eﬀects and 
might furt her increa se the risk for a third or fourt h pri- 
mary tumour .23 Ther efore, in cases of small and resect -
able tumour s in a previous ly irradiat ed area, surger y
remai ns the modality of choice 24 and complet e resection 
is impor tant for an optimal out come.25 In some cases 
howeve r, it is diﬃcult to achieve clear surgi cal margin s
in this region.20 Our study conﬁrmed a signiﬁcant bette r
5-year EFS (83%) and OS (80%) in patie nts treated with
complet e microsco pic tumou r resection. In this grou p,
we saw signiﬁcantly more patients with complete diseas e
remissi on with a mean interval of 82 months . This stres- 
ses the nee d of early detect ion of SPTs in a stage wher e
complet e resection is possible. Addit ional pre-oper ative 
chemot herapy in combinat ion with rad ical resection 
may increa se the surviv al rate of patie nts treated for 
SPTs occurring afte r heredit ary retin oblasto ma.20
A diagnost ic protocol based on clinic al sympto ms is
impor tant in Rb patie nts previous ly irradiat ed and spe- 
ciﬁc infor mation regardi ng these sympt oms should be
provided as warning signs for the patien t of interest .
How ever, sympt oms are usually nons peciﬁc and the 
most common is soft tissue swe lling whi ch may occu r
quite late in tumour developm ent. For the same reason,
a clini cal depiction based on regula r ENT examina tion 
woul d also prob ably be insuﬃcient . In order to detect 
SPTs at an early and potentiall y resect able stage , an
imag ing screeni ng program me could be suggeste d.
Accor ding to our data, we woul d recomm end to screen 
the populatio n of all retin oblastoma patie nts treated 
with EBR T from an age of 5 years to approxim ately 
20 years. Freq uency of imag ing is depend ent of diﬀerent
facto rs including age and associated treat ments, grow th- rate of sarcoma s, patien ts comfor t and costs of imaging 
exami nations. Alt hough there is current ly no consensus 
about the repetitio n time, a one year interval could be
suggest ed. Bec ause hereditary retino blastoma patie nts 
are extra vulnerable for radiat ion damage to the 
DNA, CT-s cans should be avoided, and MRI should 
be preferred.
The beneﬁt of such an MR dep iction prog ramme in
terms of survi val is currently not evidence- based. Early 
diagnosi s of SPTs sho uld be balanced agains t patie nts’
discom fort and anxiet y relat ed to repeat ed MRI exam- 
ination s, and agains t poten tial false positive MR ﬁnd-
ings leadi ng to unnec essary biopsi es. Such a screeni ng
should only be perfor med through a scientiﬁc mult icen- 
tre resear ch protocol including infor med consent and 
should asses s screeni ng-interva ls, exact radiat ion dose 
at the tumou r sit e, survi val, accuracy, beneﬁt, costs 
and tolerab ility of the method.
Fig. 4. Second primary tumours with complete (a and c) versus incomplete (b and d) microscopic tumour resection in the orbital region. Sebace ous 
gland carcinoma (a and c) in a 38 year old woman with invasion in intra-orb ital fat treated with surgery and still under comple te remission .
Liposarc oma (b and d) in a 28 year old woman treated with chemother apy and radiatio n therapy with tumour progression and death 3 years after 
diagnosis.
1946 F. Rodjan et al. / European Journal of Cancer 49 (2013) 1939–1947Precise compariso n of the SPT location with the radi- 
ation ﬁelds was not pos sible in this study with the con -
sequence that the exact dose at the tumour sit e could 
not be calcul ated. Furtherm ore, the small size of our 
patien t-cohort was a study limit ation for statist ical 
issues.
In conclusi on, osteos arcoma s and rhabomyos arco- 
mas are the major cranio-faci al SPTs in irra diated reti- 
noblast oma patien ts developi ng in speciﬁc location s,
particular ly in patien ts with EBR T in their ﬁrst year- 
of-life. As complet e surgical resect ion is a major prog- 
nostic factor, the diagnosi s of SPT should be obtaine d
as early as pos sible. Ther efore, awareness about the risk 
factors and associ ated revealing sympt oms, typic al loca- 
tion and radiol ogical patterns is impor tant. An MRI- 
based screeni ng pro gramme could also prove value in
detecting these tumour s in an early and resectab le stage 
to impr ove survival.Grant suppor t
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